Workflow
荃信生物-B(02509)发布中期业绩,收入2.06亿元 同比增长359.69%
Qyuns TherapeuticsQyuns Therapeutics(HK:02509) 智通财经网·2025-08-15 14:11

Group 1 - The company reported a revenue of RMB 206 million for the six months ending June 30, 2025, representing a year-on-year increase of 359.69% [1] - Research and development (R&D) expenses increased by 4.25% to RMB 151 million compared to RMB 145 million for the same period last year [1] - The net loss for the period was RMB 30.93 million, a significant reduction of 83.11% year-on-year, with a loss per share of RMB 0.13 [1] Group 2 - Revenue primarily came from licensing agreements, including upfront payments related to the overseas licensing of QX030N and a non-cash consideration for approximately 24.88% equity in Caldera Therapeutics, Inc., totaling RMB 181 million [1] - Additional revenue was generated from CDMO services and R&D services for projects QX004N and QX008N, amounting to approximately RMB 22 million [1] - The increase in R&D expenses was mainly due to higher clinical trial costs associated with the advancement of the company's clinical trials [1]